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Abstract
Background: Fibroblast growth factor 21 (FGF-21) is a metabolic regulator with multiple beneficial effects on glucose
homeostasis and lipid metabolism in animal models. The relationship between plasma levels of FGF-21 and coronary heart
disease (CHD) in unknown.
Methodology/Principal Findings: This study aimed to investigate the correlation of serum FGF-21 levels and lipid
metabolism in the patients with coronary heart disease. We performed a logistic regression analysis of the relation between
serum levels of FGF-21 and CHD patients with and without diabetes and hypertension. This study was conducted in the
Departments of Endocrinology and Cardiovascular Diseases at two University Hospitals. Participants consisted of one
hundred and thirty-five patients who have been diagnosed to have CHD and sixty-one control subjects. Serum FGF-21 level
and levels of fasting blood glucose; triglyceride; apolipoprotein B100; HOMA-IR; insulin; total cholesterol; HDL-cholesterol;
LDL-cholesterol; and C-reactive protein were measured. We found that median serum FGF-21 levels were significantly
higher in CHD than that of control subjects (P,0.0001). Serum FGF-21 levels in CHD patients with diabetes, hypertension, or
both were higher than that of patients without these comorbidities. Serum FGF-21 levels correlated positively with
triglycerides, fasting blood glucose, apolipoprotein B100, insulin and HOMA-IR but negatively with HDL-C and
apolipoprotein A1 after adjusting for BMI, diabetes and hypertension. Logistic regression analysis demonstrated that
FGF-21 showed an independent association with triglyceride and apolipoprotein A1.
Conclusions/Significance: High levels of FGF-21 are associated with adverse lipid profiles in CHD patients. The paradoxical
increase of serum FGF-21 in CHD patients may indicate a compensatory response or resistance to FGF-21.
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Introduction
The fibroblast growth factor (FGF) family is composed of 22
members with a wide range of biological functions, including cell
growth, development, angiogenesis, and wound healing [1–7].
FGF-21 is a member of the endocrine FGF subfamily, which also
includes FGF23, human FGF19, and its mouse homolog FGF15
[8–12]. In mice, FGF-21 is expressed predominantly in the liver
and stimulates glucose uptake through the induction of GLUT1 in
adipocytes [8]. In vivo, treatment with FGF-21 resulted in
amelioration of glucose and lipid parameters in both murine and
nonhuman primate models of diabetes and obesity [13,14].
Furthermore, FGF-21-treated animals exhibited increased energy
expenditure, fat utilization, lipid excretion, reduced hepatostea-
tosis, and ameliorated glycemia in diet-induced obese and ob/ob
mice [13]. On the other hand, adenovirus-mediated down
regulation of FGF-21 in the liver led to the development of fatty
liver, dyslipidemia, and reduced serum ketones due to the altered
expression of key genes involved in hepatic lipid and ketone
metabolism [15–17]. Taken together, these findings demonstrate
an important role of FGF-21 as a hepatic hormone in the
regulation of lipid metabolism and also suggest that FGF-21
exhibits the therapeutic characteristics necessary for an effective
treatment of obesity and fatty liver disease.
Recent human studies indicate that increased circulating levels
of FGF-21 are found in obese individuals and subjects with
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associated with obesity [18,20] and renal dysfunction in chronic
hemodialysis [21]. However, no data have been published about
the relationship between this growth factor and coronary heart
disease (CHD).
To explore the physiological and pathological characteristics of
FGF-21 in patients with CHD, we measured the serum concentra-
tions of FGF-21 in 196 Chinesesubjects and analyzed its association
with a cluster of metabolic parameters. Unexpectedly, our data
demonstrated that serum FGF-21 levels are significantly increased
in CHD individuals and are independently associated with adverse
lipid metabolism.
Methods
Participant Selection and Sample Collection
Based on the clinical diagnostic criteria shown as following,
individuals suffered from angina pectoris or myocardial infarctions
were enrolled into this study as CHD subjects. Myocardial
infarction was diagnosed on the basis of electrocardiogram findings,
elevation of serum enzymes, and chest discomfort consistent with
myocardial infarction. Angina pectoris was defined as recurrent
chest discomfort related to exercise or excitement that lasted up to
15 minutes that was responsive to rest or nitroglycerin and together
with objective evidence of myocardial ischemia ($1m mo fS T -
segment depression or $2 mm of T-wave inversion on an
electrocardiogram at rest or inducible ischemia on exertion or
pharmacologic stress testing). 135 CHD patients (67 males/68
females) were recruited in this study. 61 subjects (31 males and 30
females) served as controls. All control subjects were selected based
on the results of physician’s questionnaire and clinical biochemical
examination. The CHD patients who received medication within at
least one year for lipid lowering, anti-hypertension and diabetic
treatment were excluded. Written informed consent was given to all
patients and control individuals, and all the procedures were
approved by the Ethics Committee of Wenzhou Medical College.
Anthropometric and biochemical measurements
All subjects were assessed after overnight fasting for at least 10 h.
The details of anthropometric measurements (height, weight, BMI,
waist circumference, and blood pressure) and the methods for assay
of biochemical variables (fasting glucose, insulin, total cholesterol,
triglycerides, LDL and HDL cholesterol and lipoprotein (a) (Lp(a))
were obtained as reported previously [22]. Insulin resistance was
estimated using homeostasis model assessment index–insulin
resistance (HOMA-IR) [23,24]. Serum levels of FGF-21 (Bioven-
dor, Modrice, CzechRepublic) and C-reactiveprotein(CRP, R&D,
USA)were determined with commercially available enzyme-linked
immunosorbent assaysaccordingto the manufacturers’instructions.
After an overnight fasting, blood samples were taken. Serum
insulin was measured with a two-site chemiluminescent enzyme
immunometric assay using Immulite automated analyzer (Diagnostic
Products, Los Angeles, CA). Fasting blood glucose, total choles-
terol, HDL-c, apolipoprotein A1 (ApoA1), apolipoprotein B100
(ApoB100), LDL-c, and triglycerides were measured by standard
laboratory methods in a certified clinical examination laboratory.
Statistical analysis
All analyses were performed with Statistical Package for Social
Sciences version 13.0 (SPSS, Chicago, IL) similarly as described by
Table 1. Clinical and biochemical characteristics of CHD and control groups.
Variables
Controls
(n=61)
CHD
(n=135) P value
Anthropometric Age(years) 68.6610.8 6965.8 -
Gender, male(%) 31(50.8%) 67(49.6) -
BMI(kg/m
2) 22.362.4 24.663.1 -
Type 2 diabetes mellitus (%) - 62(45.9) -
Hypertension (%) - 63(46.7) -
Systolic pressure (mmHg) 123621 135661 0.009
Diastolic pressure (mmHg) 73612 74623 NS
Lipid metabolism Total Cholesterol (mmol/L) 4.3760.62 4.7761.02 0.036
HDL-cholesterol(mmol/L) 1.5160.39 1.07 60.27 ,0.001
LDL-cholesterol (mmol/L) 2.6360.47 2.9560.94 0.009
Triglyceride (mmol/L) 1.1560.44 1.9461.59 ,0.001
ApoA1(g/L) 1.4960.12 1.1960.27 ,0.001
ApoB100(g/L) 0.7660.11 0.9560.33 ,0.001
Lip A (mg/L) 204.56105.6 212.16138.6 NS
Glucose metabolism Fasting glucose (mmol/L) 5.0860.51 6.3162.18 ,0.001
Fasting insulin (mIU/L) 5.4463.24 9.9568.59 0.001
HOMA-IR 1.2260.10 2.8861.31 ,0.001
HOMA-IS 73.96654.5 101.8689.9 0.035
Inflammation Hs-CRP(mg/l) 1.1660.83 6.6762.71 ,0.001
FGF-21(ng/L)* 131.0(70.4 to 249.5) 362.5(210.6 to 661.9) ,0.001
Data are means 6 SD or *median (interquartile range).
NS, not significant.
doi:10.1371/journal.pone.0015534.t001
FGF-21 and CHD
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mean6SD. Data that were not normally distributed, as determined
using Kolmogorox-Smirnov test, were logarithmically transformed
before analysis and expressed as median with interquartile range.
Student’s unpaired t test was used for comparison between two
groups. Pearson’s correlation was used as appropriate for
comparisons between groups, and multiple testing was corrected
using Bonferroni correction. Multiple stepwise regression analysis
was used to examine the association of serum FGF-21 and other
parameters. The variables correlated significantly with serum FGF-
21 (after Bonferroni correction for multiple testing) were selected to
enter into stepwise regression. In all statistical tests, P values ,0.05
were considered significant.
Results
Serum FGF-21 levels are increased in CHD patients
Biochemical and clinical characteristics of the CHD patient
and healthy groups are summarized in Table 1. Serum FGF-21
levels ranged from 11.63 to 2614.9 ng/l in 196 subjects, and
there were no sex differences in serum FGF-21 levels (men
[n=94], median 415.3 ng/l [interquartile range 58.5, 250.1] vs.
women [n=92], 361.0 ng/l [79.4, 218.3], P=0.252). Interest-
ingly, median circulating FGF-21 level was 3-fold higher in CHD
patients (513.5647.5 ng/l) compared with control subjects
(167.9615.6 ng/l) (P,0.0001) after adjusted for body mass index
(BMI) (Table 1 and Figure 1A). On other hand, CHD subjects
with diabetes (530.0 ng/l, [interquartile rang 75.6–1941.3],
n=61) had significantly higher serum FGF-21 levels (P=0.034)
than those of CHD subjects without diabetes (317.2 ng/l, [59.1–
680.5], n=74) (Figure 1B), consistent with the finding by Chen
et al [25]. No significant difference in serum FGF-21 levels was
observed between CHD patients with hypertension (462.2 ng/l,
[59.1–2614.9], n=97) and CHD patients without hypertension
(428.2 ng/l, [77.8–1069.2] n=38), despite an elevated trend in
these CHD patients with hypertension (P=0.0718, Figure 1C).
Furthermore, serum FGF-21 levels in CHD patients with both
diabetes and hypertension (502.3 ng/l, [157.6–2614.9], n=45)
were significantly higher than that of CHD patients without
diabetes and hypertension (410.5 ng/l, [77.8–1069.2], n=21,
p=0.026, Figure 1D). Logistic regression analysis showed that
serum FGF21 level was independently associated with the
prevalence of CHD (p=0.004).
Association of serum FGF-21 levels with adverse lipid
metabolism and insulin resistance
As shown in Table 2 and Figure 2, a significant positive
association of serum FGF-21 levels with triglyceride and
apolipoprotein B100 (r=0.365, P,0.001; r=0.227, P=0.002,
Figure 1. Serum FGF-21 concentrations in subjects with CHD and normal controls. A, Serum FGF-21 levels of 135 CHD patients and 61
control subjects. B, Serum FGF-21 levels of CHD patients with diabetes (CHD+DIA, n=61) and CHD patients without diabetes (CHD, n=74). C, Serum
FGF-21 levels of CHD patients with hypertension (H, n=97) and CHD patients without hypertension (NH, n=38). D, Serum FGF-21 levels of CHD
patients with diabetes and hypertension (H+D, n=45) and CHD patients without diabetes and hypertension (NH+ND, n=21).
doi:10.1371/journal.pone.0015534.g001
FGF-21 and CHD
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21 levels correlated negatively with HDL- c and apolipoprotein A
levels (r=20.313, P,0.001; r=20.338, P,0.00,1 respectively)
after adjustment for BMI. However, the associations of serum
FGF-21 with TC and LDL-c were not significant in our research
subjects. In addition, serum FGF-21 levels correlated with fasting
glucose, fasting insulin as well as HOMA-IR after adjustment for
BMI, but no significant correlation was found between serum
FGF-21 levels and HOMA-IS.
Serum FGF-21 levels are independently associated with
ApoA1, TG and fasting glucose
To determine whether serum FGF-21 was independently
associated with anthropometric parameters and cardiovascular
risk factors, stepwise logistic regression analysis involving all the
parameters with significant correlations with serum FGF-21 was
performed (Table 3). Stepwise logistic regression analysis revealed
that ApoA1 (b coefficient 20.304, 95% CI 20.500 to –0.173,
P,0.001), fasting glucose (b coefficient 0.219, 95% CI 0.013 to
0.087, P=0.008) and triglyceride (b coefficient 0.213, 95% CI
0.016–0.124, P=0.011) independently associated with serum
FGF-21 after adjustment for BMI, diabetes and hypertension.
However, all other parameters including total cholesterol, HDL-
cholesterol, LDL-cholesterol, ApoB100, insulin and HOMA-IR
were excluded during regression analysis.
Discussion
Our primary aim was to observe the clinical manifestation of
FGF-21 in conjunction with physiological and pathological aspects
in CHD patients. Our results suggest that FGF-21 is correlated
with CHD as supported by two novel findings. First, we
demonstrate that in addition to fasting glucose, both apolipopro-
tein A1 and triglyceride are significantly associated with circulating
FGF-21 in our research subjects independent of BMI, HDL
cholesterol and insulin in multivariate analysis. Furthermore, we
show that FGF-21 levels are 3-fold higher in CHD individuals with
severely impaired cardiovascular systems.
While numerous data have been published in animal model,
little is known about FGF-21 in human subjects, particularly for
patients with heart diseases. Previous studies indicated that
circulating FGF-21 is significantly higher in obese populations
with increased cardiovascular risk [20]. Here we showed, for the
first time, the pathological manifestation of FGF-21 in CHD
individuals.
Serum FGF-21 levels were found to closely related to lipid
metabolism. A recent study has already demonstrated that serum
triglycerides and total cholesterol were independently associated
with FGF-21 [19]. In this study, we found that apolipoprotein A1
was negatively correlated with FGF-21 concentration. Apolipo-
protein A1 is the major protein component of the high-density
lipoprotein (HDL) particles, which promotes cholesterol efflux
from tissues to the liver for excretion. Studies have shown inverse
associations between apoA1 levels and CHD [26,27], and
enhancing ApoA1 is preventive against CHD. FGF21 treatment
provides beneficial changes in some lipoproteins and cardiovas-
cular risk factors in rodents and nonhuman primates. However, it
does not change circulating ApoA1 levels [14]. The correlation
between FGF21 and ApoA1 in CHD deserves further studies.
We have also showed that diabetes and hypertension have
additional effects on FGF-21 levels in CHD patients, which is
supported by the fact that serum FGF-21 levels in CHD
individuals with diabetes, hypertension, or both were higher than
in the CHD individuals without these complications. However,
diabetes and hypertension are unlikely to be a primary factor for
the increment of FGF-21 in CHD patients, since CHD patients
without diabetes and hypertension had significantly higher FGF-
21 levels than normal controls.
The physiological and pathological significance of increasing
serum FGF-21 levels in cardiovascular disease remains to be
Table 2. Correlations of serum FGF-21* levels with anthropometric parameters and biochemical indexes.
Variables Serum FGF-21 Serum FGF-21#
rp rP
Age 2.004 NS - -
Gender 2.089 NS - -
BMI 0.239 0.001 - -
Fasting Glucose 0.347 ,0.001 0.305 ,0.001
Fasting Insulin 0.209 0.012 0.192 0.027
Total Cholesterol 0.119 NS 0.144 NS
HDL-Cholesterol 20.313 ,0.001 20.285 ,0.001
LDL-Cholesterol 0.049 NS 0.035 NS
Triglyceride 0.365 ,0.001 0.312 ,0.001
Apolipoprotein A1 20.338 ,0.001 20.310 ,0.001
Apolipoprotein B100 0.227 0.006 0.196 0.012
Hs-CRP 0.102 NS 0.092 NS
Lp(a) 20.154 NS 20.122 NS
HOMA-IS 2.018 NS 20.012 NS
HOMA-IR 0.255 0.002 0.232 0.006
*Log transformed before analysis.
# adjusted by BMI, diabetes and hypertension.
NS: not significant.
doi:10.1371/journal.pone.0015534.t002
FGF-21 and CHD
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are significantly higher in obese population with increased
cardiovascular risk characterized by the evidence of metabolic
syndrome in the obese subjects. Because FGF-21 is an adipokine
with glucose-lowering effects [8,13,28–30], it was speculated that
the paradoxical increase of this protein in populations with risk of
cardiovascular disease is a compensatory mechanism to counteract
metabolic stress. Furthermore, FGF-21 resistance might be found
in obesity and in renal failure, leading to compensatory
upregulation of this adipokine [20,21]. This gives us a speculative
clue that may suggest that the mechanism of increased FGF-21
levels in cardiovascular disease is similar to obesity-associated
resistance to insulin. Further studies are needed to elucidate the
precise mechanism by which CHD subjects elevate circulation
FGF-21 levels and reveal the role of increased FGF-21 levels in
CHD.
There are several limitations in this study. Rather small
collective of patients enrolled in this study is a major limitation
of the study. A large sample size may be needed for more
comprehensive investigation. In addition, our study did not
address the cause-effect relationship between FGF-21 and the
onset and development of CHD. Further studies are warranted to
determine whether elevated serum FGF-21 is causally related to
dyslipidemia or is a compensatory response to CHD.
In summary, this study provides clinical evidence revealing that
serum concentrations of FGF-21 are increased in CHD subjects.
Together with previous findings [20], our data suggest that serum
concentrations of FGF21 in humans are not related to insulin
Figure 2. Correlation of serum FGF-21 levels with adverse lipid metabolism and insulin resistance. Regression analysis of serum levels of
FGF-21 (log transformed) with HDL-cholesterol (A), Fasting glucose (B), Triglyceride (C) and Apolipoprotein AI (D) in 196 subjects.
doi:10.1371/journal.pone.0015534.g002
Table 3. Multiple stepwise regression analysis showing variables independently associated with the serum level of FGF-21.
Independent Variables Standardized b B (95% CI) t P
Triglyceride 0.213 0.070 (0.016 to 0.124) 2.575 0.011
Apolipoprotein A1 20.304 20.343 (20.500 to 20.173) 24.117 ,0.001
Fasted blood glucose 0.219 0.0503(0.013 to 0.087) 2.676 0.008
The analyses also included BMI, Total Cholesterol, HDL-cholesterol, LDL-cholesterol, ApoB100, insulin, HOMA-IS and HOMA-IR, which were all excluded in the final
model.
doi:10.1371/journal.pone.0015534.t003
FGF-21 and CHD
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in FGF21 seen in human CHD patients raises the intriguing
possibility that FGF21 could be a biomarker for CHD.
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